Medical Education Library

Update On Insulin Management in Type 2 Diabetes

May 2012 ยท Vol. 61, No. 05 Suppl: S2-S2
This supplement was sponsored by the Primary Care Metabolic Group and the Primary Care Education Consortium and is supported by funding from Novo Nordisk Inc. It was edited and peer reviewed by The Journal of Family Practice.
PDF Download

 

Insulin has been a cornerstone of therapy for diabetes mellitus since its discovery a century ago. The insulin analog formulations available today are vastly improved over the animal-derived insulins used for decades; pens and other devices used to administer insulin are also vastly improved. Further clinical benefits may be possible with insulins expected to be available in the near future, such as insulin degludec. There are many challenges with insulin therapy in the primary care setting, but strategies can be employed to address patient barriers, as well as to initiate and modify insulin therapy based upon patient response.

Recommended Reading

New Guidelines Embrace Patient-Centered Diabetes Care
Type 2 Diabetes ICYMI
New Warning, Contraindications Announced for Aliskiren-Containing Drugs
Type 2 Diabetes ICYMI
Study Looks at Cost of Lowering HbA1c Cutoffs
Type 2 Diabetes ICYMI
Insulin Degludec Matches Insulin Glargine Efficacy
Type 2 Diabetes ICYMI
A Shared Diabetes Clinic at a Veterans Affairs Medical Center
Type 2 Diabetes ICYMI
Exercise Plus Virtual Reality Improves Cognition; Metabolic Syndrome Starts Early; Enteral Feeding in Acute Lung Injury
Type 2 Diabetes ICYMI
Should We Care Whether Statins Cause Diabetes?
Type 2 Diabetes ICYMI
Glucocorticoid-induced diabetes and adrenal suppression
Type 2 Diabetes ICYMI
Glucocorticoid-induced diabetes and adrenal suppression
Type 2 Diabetes ICYMI
In reply: Glucocorticoid-induced diabetes and adrenal suppression
Type 2 Diabetes ICYMI